About Xeltis
Xeltis is a Healthcare company based in Zurich (Switzerland) founded in 2006. It operates as a developer of bioabsorbable synthetic heart valves and vascular grafts. Xeltis has raised $199.38 million across 14 funding rounds from investors including EQT, European Investment Bank and Kurma Partners. Xeltis offers products and services including Artificial Vessels, Heart Valves, and RestoreX Platform. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include PECA Labs, Occlutech, Endonovo Therapeutics, Coherex and CoAptus Medical and 3 more; 5 of its 8 listed competitors have raised funding.
Company details
Xeltis was founded in 2006 in Zurich, Switzerland, where bioabsorbable synthetic heart valves and vascular grafts are developed for cardiovascular applications. These implants are designed to mimic natural valves and vessels, enabling the body to heal by forming native tissue as the synthetic matrix is gradually absorbed. Operations center on pediatric solutions, including a flagship pulmonary valve replacement for congenital heart malformations. The sector involves regenerative medical devices.
- Headquarters Zurich, Switzerland
- SectorsHealthcare
- Website xeltis.com
- Social LinkedIn X Facebook
- Total Equity Funding$199.38M (USD)
in 14 rounds
- Latest Funding Round$23.34M (USD), Series E
Jul 2026
- InvestorsEQT
& 14 more
Products & Services of Xeltis
Xeltis offers a comprehensive portfolio of products and services, including Artificial Vessels, Heart Valves, and RestoreX Platform.
Devices that regenerate into patients' tissue to treat vascular conditions.
Implants for pulmonary replacement to reduce surgical complications.
ETR-based system for developing self-healing vascular solutions.
Funding Insights of Xeltis
Xeltis has successfully raised a total of $199.38M across 14 strategic funding rounds. The most recent funding activity was a Series E round of $23.34 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $199.38M
- Total Rounds 14
- Last Round Series E — $23.34M
- First Round $33.64M
(Dec 2014)
- Investors Count 15
Latest 10 of 14 funding rounds of Xeltis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $23.34M | Series E | – | Horizon 3 Healthcare | |
| Dec 2025 | $58.07M | Debt – Conventional | – | – | |
| Dec 2025 | $11.61M | Series D | – | – | |
| Aug 2023 | $13.68M | Series D | – | – | |
| Feb 2023 | $34.19M | Series D | – | DaVita Venture Group, EQT | – |
| Aug 2022 | $15.28M | Series D | – | China Grand Pharmaceutical and Healthcare | – |
| Dec 2021 | $2.83M | Grant | – | – | |
| Nov 2021 | $16.96M | Debt – Conventional | – | – | |
| Jan 2021 | $784,874 | Grant | – | – | |
| Sep 2019 | $11.56M | Series D | – | Life Sciences Partners |
15 investors in total: 15 institutional.
Investors in Xeltis
Xeltis has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, European Investment Bank and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Venture capital firm investing in healthcare sectors | – | davitaventuregroup.com | Denver, United States | |
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Infrastructure and venture capital funding is provided in key sectors. | – | invest-nl.nl | Amsterdam, Netherlands | |
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Ysios Capital is recognized as a leading life sciences investor. | – | ysioscapital.com | Barcelona, Spain | |
Early-stage venture capital is invested in US and Europe. | – | vipartners.ch | Altendorf, Switzerland | |
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
- | – | h3healthcare.com.au | - |
Investor details for Xeltis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xeltis
41 people are tracked at Xeltis (11 in leadership, 22 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Lucien van Os | Chief Operations Officer | Leadership |
Thilo Tübler | Director Medical Affairs | Leadership |
Eliane Schutte | CEO | Leadership |
Alexander Goemans | Chief Financial Officer | Leadership |
Martijn Cox | Chief Technology Officer & Co-Founder | Leadership |
Paulo Neves | VP, Clinical & Medical Affairs | Leadership |
Albert Gootzen | Director Quality | Leadership |
Judith Zwaan RC | Finance Director | Leadership |
Shawn M. Gage | VP Of US Clinical Affairs | Leadership |
Wian van den Bergh | Assoc. Director R&d | Leadership |
Ian Johns | Senior Director Of Operations | Leadership |
George Fazio | Chairman | Board & advisors |
Vanessa Malier | Board Member | Board & advisors |
Christian Wenger | Board Member | Board & advisors |
Diego Braguglia | Board Member | Board & advisors |
Clemens van Blitterswijk | Board Member | Board & advisors |
Thierry Carrel | Medical Advisor | Board & advisors |
Rüdiger Lange | Medical Advisor | Board & advisors |
Michael Mack | Medical Advisor | Board & advisors |
Patrick Serruys | Medical Advisor | Board & advisors |
21 more people are available in the full profile.
Complete people profiles for Xeltis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Xeltis
3 dated milestones of Xeltis across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Xeltis is founded.
- Funding First funding round of $33.6M.
- Funding Latest funding round, Series E, of $23.3M.
Competitors of Xeltis
Xeltis has 8 listed competitors in our database, 5 of them funded. They include PECA Labs, Occlutech, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pecalabs.com | 2011 | Pittsburgh, United States | $19.91M | – | Pediatric cardiac surgical devices are developed for congenital heart defects. | |
| occlutech.com | 2003 | Schaffhausen, Switzerland | $70.81M | – | Provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure | |
| endonovo.com | 2011 | Los Angeles, United States | – | – | Bioelectronic devices are developed for regenerative medicine therapies. | |
| coherex.com | 2003 | Salt Lake, United States | $25.03M | 19 | Structural heart disease conditions are addressed with implant devices. | |
| coaptus.com | 2003 | Redmond, United States | $3M | 40 | Develops non-implant therapeutics for treating patent foramen ovale, a structural heart defect. | |
| cardia.com | 1998 | Eagan, United States | – | – | Products for transvenous closures of certain types of congenital heart defects. | |
| elevatedcpr.com | 2015 | Edina, United States | $9.51M | – | CPR products for sudden cardiac arrest treatment are developed. | |
| mallowmedical.com | 2003 | Xuhui, China | – | – | Medical devices for congenital heart defects are developed and offered. |
Detailed competitors of Xeltis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Xeltis
The website of Xeltis (xeltis.com) receives about 6.8K visits a month.
- Monthly visits6.8K
▼ 1.4% vs previous month
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as Xeltis (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xeltis
Complete news archive for Xeltis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xeltis
Xeltis was founded in 2006 and raised its 1st funding round 8 years after it was founded.
Xeltis is headquartered in Zurich, Switzerland.
Xeltis is a funded company, having raised a total of $199.38M across 14 funding rounds to date. The company's 1st funding round was a Series D of $11.56M, raised on Dec 2014.
Xeltis was founded in 2006 in Zurich, Switzerland, where bioabsorbable synthetic heart valves and vascular grafts are developed for cardiovascular applications. These implants are designed to mimic natural valves and vessels, enabling the body to heal by forming native tissue as the synthetic matrix is gradually absorbed. Operations center on pediatric solutions, including a flagship pulmonary valve replacement for congenital heart malformations. The sector involves regenerative medical devices.
Xeltis's top competitors include PECA Labs, Endonovo Therapeutics and Occlutech.
Xeltis offers Artificial Vessels, Heart Valves, and RestoreX Platform.
Xeltis has 15 investors. Key investors include EQT, European Investment Bank, Kurma Partners, European Union, and Life Sciences Partners.